<DOC>
	<DOC>NCT00482976</DOC>
	<brief_summary>To determine if protein kinase C beta plays a significant role in vascular endothelial dysfunction, small fiber neural dysfunction, and oxidative stress associated with diabetes mellitus.</brief_summary>
	<brief_title>Effect of LY333531 on Vascular and Neural Functions</brief_title>
	<detailed_description>32mg Ruboxistaurin; 4 week cross-over treatment.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>Type 2 diabetes diagnosed for at least 1 mo and less than 10 yrs prior to visit 1 HbA1c less than 9% and fasting plasma glucose less than 260mg/dl Blood pressure less than 160/100 mmHg Total cholesterol less than 300 mg/dl and/or triglycerides less than 600 mg/dl Subjects treated with a thiazolidinedione (TZD) in 12 weeks prior to visit 1. History of heart disease (MI, unstable angina, CVA, TIA, CABG, or percutaneous transluminal coronary angioplasty) w/in 6 months of visit 1 or subjects with BYHA class III or IV congestive heart failure. Female subjects of childbearing potential that are pregnant or intend to become pregnant (i.e. not practicing an acceptable method of birth control) TSH greater than 1.5 times upper limit of normal at V1 or other endocrine disease. ALT greater than 1.5 times upper limit of normal at V1; Serum creatinine greater than 2.0mg/dl at V1; microalbumin greater than 300.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>